The clinical trial for mexiletine in patients with sporadic Amyotrophic Lateral Sclerosis (SALS) aims to evaluate the safety and efficacy of two dosing regimens (300 mg and 900 mg) compared to a placebo. Given the lack of effective treatments for ALS, a successful outcome could position mexiletine as a novel therapeutic option in a market with significant unmet needs. The ALS market is characterized by limited competition, primarily dominated by riluzole and edaravone, which may provide a favorable environment for mexiletine if proven effective. The trial's completion and subsequent data could attract interest from larger pharmaceutical companies for potential partnerships or acquisitions, enhancing the asset's commercial viability.